Efforts to understand the molecular basis of hypertension through drug: Membrane interactions

Current Topics in Medicinal Chemistry

Volumn 4, Issue 4, 2004, Pages 445-459

  Mavromoustakos, T ^a   Zoumpoulakis, P ^a,b   Kyrikou, I ^a,b   Zoga, A ^a,b   Siapi, E ^a   Zervou, M ^a   Daliani, I ^a   Dimitriou, D ^c   Pitsas, A ^c   Kamoutsis, C ^c   Laggner, P ^d  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c Section of Organic Chemistry   (Greece)

^d Institute of Biophysics and X ray S   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; AMPHOPHILE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; IRBESARTAN; LOSARTAN;

BILAYER MEMBRANE; BIOPHYSICS; DRUG DIFFUSION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HYPERTENSION; MOLECULAR MODEL; PERMEABILITY BARRIER; REVIEW;

EID: 3042762752     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043451339     Document Type: Review

References (86)

1. De Gasparo, M.; Catt, KJ.; Inagami, T.; Wright, JW. and Unger, T. International Union of Pharmacology. XXIII. The Angiotensin II Receptors. Pharmacol. Rev. 2000, 52, 415-472.
2. 1receptor. TiPS 1996, 17, 135-140.
3. 1Angiotensin Receptor. J. Biol. Chem. 1994, 269, 24 16533-16536.
4. 1receptor which comprise a general binding site for biphenylimidazole antagonists. FEBS Letters 1996, 394, 361-364.
5. 1angiotensin receptor. British J of Pharmac. 1996, 719, 1505-1507.
6. Noda, K.; Saad, Y.; Kinoshita, A.; Boyle, TP.; Graham, RM.; Husain, A.; Karnik, SS. Tetrazole and Carboxylate Groups of Angiotensin Receptor Antagonists Bind to the Same Subtype by Different Mechanisms. J. Biol. Chem. 1995, 270, 2284-2289.
7. Schambye, HT; Hjorth, SA.; Weinstock, J. and Schwartzn, W. Interaction between the Nonpeptide Angiotensin Antagonist SKF-108,566 and Histidine 256 (HisVI:16) of the Angiotensin Type 1 Receptor. Molec. Pharmac. 1995, 47, 425-431.
8. Flower, DR. Modelling G-protein-coupled receptors for drug design. Bioch. Bioph. Acta 1999, 1422, 207-234.
9. 1angiotensin receptor. British J. of Pharmac. 1996, 119, 1505-1507.
10. 1Receptor Activation Is Dependent upon Two Juxtaposed Asparagine Residues on Transmembrane Helices III and VII. J. Biol. Chem. 1997, 272, 4245-4251.
11. 1Receptor Is Essential for Full Agonism, J. Biol. Chem. 1995, 270, 12846-12850.
12. Feng, YH. and Karnik, SS. Role of Transmembrane Helix IV in G-protein Specificity of the Angiotensin II Type 1 Receptor. J. Biol. Chem. 1999, 274, 35546-35552.
13. 1Receptor. J. Biol. Chem. 1994, 269, 30953-30959.
14. 1Angiotensin Receptor Function on Adjacent Asparagine Residues in the Seventh Transmembrane Helix. Mol. Pharm. 1998, 54, 427-434.
15. 1Receptor. J. Biol. Chem. 1999, 274, 7103-7110.
16. Monnot, C.; Bihoreau, C.; Conchon, S.; Curnow, KM.; Corvol, P. and Clauser, E. Polar Residues in the Transmembrane Domains of the Type 1 Angiotensin II Receptor Are Required for Binding and Coupling. J. Biol. Chem. 1996, 271, 1507-1513.
17. 1Receptor in Agonist Activation. J. Biol. Chem. 1995, 270, 28511-28514.
18. Sakarellos, C.; Lintner, K.; Piriou, F.; Fermandjian, S. Conformation of the central sequence of Angiotensin II and analogues. Biopolymers 1983, 22, 663-687.
19. Fermandjian, S.; Fromageot, P.; Tistchenko, A. M.; Leicknam, J. P.; Lutz, M. Angiotensin II Conformations. Infrared and Raman Studies. Eur. J. Biochem. 1972, 28, 174-182.
20. 1H Nuclear Magnetic Resonance. Proc. Natl. Acad. Sci. USA 1980, 77, 82-86.
21. Surewicz, W. K.; Mantsch, H. H. Conformational Properties of Angiotensin-II in Aqueous-Solution and in a Lipid Environment - A Fourier-Transform Infrared Spectroscopic Investigation. J. Am. Chem. Soc. 1988, 110, 4412-4414.
22. Cushman, J. A.; Mishra, P. K.; Bothner-By, A. A.; Khosla, M. S. Conformations in Solution of Angiotensin II, and its 1-7 and 1-6 Fragments. Biopolymers 1992, 32, 1163-1171.
23. Printz, M. P.; Nemethy, G.; Bleich, H. Proposed Models for Angiotensin II in Aqueous Solution and Conclusions About Receptor Topography. Nat. New Biol. 1972, 237, 135-140.
24. Printz, M. P.; Williams, H. P.; Craig, L. C. Evidence for the Presence of Hydrogen-Bonded Secondary Structure in Angiotensin II in Aqueous Solution. Proc. Natl. Acad. Sci. USA 1972, 69, 378-382.
25. Marshall, G. R.; Bosshard, H. E.; Vine, W. H.; Glickson, J. D. NMR Evidence Against Gamma Turn and Beta Turn Models of Angiotensin II in Aqueous Solution. Nat. New Biol. 1973, 245, 125-127.
26. 5] Angiotensin II, Angiotensin III and Saralasin. Biochim. Biophys. Acta 1981, 667, 157-167.
27. Lenkinski, R. E.; Stephens, R. L.; Krishna, N. R. Conformation of Angiotensin II. Evidence for a Specific Hydrogen Bonded Conformation. Biochemistry 1981, 20, 3122-3126.
28. Weinkam, R. J.; Jorgensen, E. C. Angiotensin II Analogs. VIII. The Use of Free Radical Containing Peptides to Indicate the Conformation of the Carboxyl Terminal Region of Angiotensin II. J. Am. Chem. Soc. 1971, 93, 7033-7038.
29. Weinkam, R. J.; Jorgensen, E. C. Angiotensin II Analogs. IX. Conformational Studies of Angiotensin II by Proton Magnetic Resonance. J. Am. Chem. Soc. 1971, 93, 7038-7044
30. Nikiforovich, G. V.; Vesterman, B.; Betins, J.; Podins, L. The Space Structure of a Conformationally Labile Oligopeptide in Solution: Angiotensin. J. Biomol. Struct. Dyn. 1987, 4, 1119-1135.
31. Nikiforovich, G. V.; Marshall, G. R. Three-Dimensional Recognition Requirements for Angiotensin Agonists: A Novel Solution for an Old Problem. Biochem. Biophys. Res. Commun. 1993, 195, 222-228.
32. Lintner, K.; Fermandjian, S.; Fromageot, P.; Khosla, M. C.; Smeby, R. R.; Bumpus, F. M. Circular Dichroism Studies of Angiotensin II and Analogues: Effects of Primary Sequence, Solvent, and pH on the Side-Chain Conformation. Biochemistry 1977, 16, 806-812.
33. Turner, R. J.; Matsoukas, J. M.; Moore, G. J. Fluorescence Properties of Angiotensin-II Analogs in Receptor-Simulating Environments - Relationship Between Tyrosinate Fluorescence Lifetime and Biological-Activity. Biochim. Biophys. Acta 1991, 1065, 21-28.
34. 2Terminal Domain of Angiotensin-II (Ang-II) and [Sar(1)]Angiotensin-II on Conformation and Activity - NMR Evidence for Aromatic Ring Clustering and Peptide Backbone Folding Compared with [Des-1,2,3]Angiotensin-II. J. Biol. Chem. 1994, 269, 5303-5312.
35. Matsoukas, J. M.; Moore, G. J. NMR-Studies on Angiotensin-II - Histidine and Phenylalanine Ring Stacking and Biological-Activity. Biochem. Biophys. Res. Commun. 1984, 122, 434-438.
36. Surewicz, W. K.; Mantsch, H. H. Effect of Membrane-Binding on the Conformation of Angiotensin-II and its Analogs - A Fourier-Transform Infrared Spectroscopic Stuay. Biophys. J. 1988, 53, A632-A632.
37. Cho, N. J.; Asher, S. A. UV Resonance Raman and Absorption Studies of Angiotensin II Conformation in Lipid Environments. Biospectroscopy 1996, 2, 71-82.
38. Holtz, J. S. W.; Lednev, I. K.; Asher, S. A. UV Resonance Raman Study of Angiotensin II Conformation in Nonaqueous Environments: Lipid Micelles and Acetonitrile. Biopolymers 2000, 57, 55-63.
39. Carpenter, K. A.; Wilkes, B. C.; Schiller, P. W. The Octapeptide Angiotensin II Adopts a Well-Defined Structure in a Phospholipid Environment. Eur. J Biochem. 1998, 251, 448-53;
40. Wilkes C. B.; Masaro L.; Schiller, P. W.; Carpenter K. A. Angiotensin II vs its Type I Antagonists: Conformational Requirements for Receptor Binding Assessed from NMR and Receptor Docking Experiments. J. Med. Chem. 2002, ASAP article.
41. Garcia, K. C.; Desiderio, S. V.; Ronco, P. M.; Verroust, P. J.; Amzel, L. M. Recognition of Angiotensin-II - Antibodies at Different Levels of An Idiotypic Network are Superimposable. Science 1992, 257, 528-531.
42. Pierson, M. E.; Freer, R. J. Analysis of the Active Conformation of Angiotensin II: A Comparison of AII and Non-Peptide AII Antagonists. Pent. Res. 1992, 5, 102-105.
43. Theodoropoulou, E.; Marsh, D. Interactions of angiotensin II non-peptide antagonist losartan with phospholipid membranes by combined use of differential scanning calorimetry and electron spin resonance spectroscopy. Biochim. Biophys. Acta 1999, 1461, 135-146.
44. Mavromoustakos, T.; Daliani, I.; Matsoukas, J. The application fo biophysical methods to study Drug:Membrane Interactions. In: Matsoukas, J.; Mavromoustakos, T. (Eds.), Bioactive peptides in Drug Discovery and Design: Medical Aspects. IOS Press-Ohmsha 1999, 22, 13-24.
45. Nagle, F.J. Nagle T.S. Structure of lipid bilayers. Biochim. Biophys. Acta 2000, 1469, 159-195.
46. McElhaney, R.N.: The use of differential scanning calorimetry and differential thermal analysis in studies of model and biological membranes. Chem. Phys. Lipids 1982, 39(2-3), 229.
47. Franks, N.P. Levine, Y.K. Low angle x-ray diffraction. In Membrane Spectroscopy (Ernst Grell, ed.), p.437, Springer-Verlag, New York, 1981.
48. Franks, X-ray Optics. Sci. Prog., Oxf. 1977, 64, 371.
49. Solid state nuclear magnetic resonance of lipid bilayers. Methods of Enzymology 1981, 72, 108.
50. Yannoni, C.S. High-resolution NMR in Solids: The CPMAS Experiment. Acc. Chem. Res. 1982, 15, 201-208.
51. M. J. Janiak, D. M Small, G. G. Shipley, Nature of the thermal pretransition of synthetic phospholipids: dimyristoyl- and dipalmitoyllecithin, Biochemistry 1976, 15, 4575-4580.
52. K. Jorgensen, J. H. Ipsen, O. G. Mouritsen, D. Bennett, M. J. Zuckermann, A general model for the interaction of foreign molecules with lipid membranes: drugs and anaesthetics, Biochim. Biophys. Acta 1991, 1062, 227-238.
53. S. Ali, S. Minchey, A. Janoff, E. A. Mayhew, Differential Scanning Calorimetry Study of Phosphocholines Mixed with Paclitaxdel and Its Bromoacylated Taxanes, Biophysical J. 2000, 78, 246-256.
54. N.W. Huh, N. A. Porter, T. J. McIntosh, S. A. Simon, The Interaction of Polyphenols with Bilayers: Conditions for Increasing Bilayer Adhesion, Biophysical J. 1996, 71, 3261-3277.
55. T. Mavromoustakos, E. Theodoropoulou, D. Papahatjis, T. Kourouli, De-Ping Yang, M. Trumbore, A. Makriyannis: Studies on the thermotropic effects of cannabinoids on phosphatidylcholine bilayers using differential scanning calorimetry and small angle X-ray diffraction. Biochim. Biophys. Acta 1996, 1281(2) 235-244.
56. Lohner, K., Prenner, E.J. Differential scanning calorimetry and x-ray diffraction studies of the specificity of the interaction of antimicrobial peptides with membrane-mimetic systems.
57. M. K. Jain, N. Minn Wu, Effect of Small Molecules on the Dipalmitoyl Lecithin Liposomal Bilayer. J. Membrane Biol. 1977, 34, 157-201.
58. M. K. Jain, N. Yen-Min Wu, T.K. Morgan, M. S. Briggs, R.K. Murray, Phase Transition in a Lipid Bilayer. II. Influence off Adamantane Derivatives. Chem. Phys. Lipids 1976, 17, 71-78.
59. Franks, N.P., Arunachalam, T., Caspi, E.: A direct method for determination of membrane electron density on an absolute scale. Nature 1978, 2 76, 530 ().
60. Franks, N.P., Lieb, W.R.: The structure of lipid bilayers and the effects of general anaesthetics. An x-ray and neutron diffraction study. J. Mol. Biol. 1979, 133, 469.
61. Herbette, L., Katz, A.M., Sturtevart, J.M.: Comparisons of the interaction of propanolol and timolol with model and biological membrane systems. Mol. Pharmacol. 1983, 24, 259.
62. Herbette, L.G., Chester, D.W. Rhodesx, D.G.: Structural Analysis of Drug Molecules in Biological Membranes Biophys. J. 1986, 49, 91.
63. Mason, P.R., Conye, G.E., Chester, D.W., Herbette L.G.: Partitioning and location of Bay K 8644, 1,4-dihydropyridine calcium channel agonist, in model and biological membranes. Biophys. J. 1989, 55, 55.
64. Shipley, G.G., 1973. Recent X-ray diffraction studies of biological membranes and membrane components, in:Biological Membranes (D. Chapman and D.F.H. Wallach, eds.), pp. 1-89, Academic Press, New York.
65. Young, H.S. Skita, V., Mason, R.P. and Herbette, L.G.,, Molecular Basis for the inhibition of 1,4-dihydropyridine calcium channel drugs binding to their receptors by a nonspecific site interaction mechanism. Biophys. J. 1992, 61, 1244-1255.
66. Laggner, P. X-Ray Diffraction on Biomembranes with Emphasis on Lipid Moiety. Subcellular Biochemistry, vol. 23. Physicochemical Methods in the Study of Biomembranes, edited by J. Hilderson and Gregory B. Ralston. Plenum Press, New York, 1994.
67. Mavromoustakos, T.; Papahatjis, D.; Laggner, P. Differential membrane fluidization by active and inactive cannabinoid analogues. Biophys. Biochim. Acta 2001, 1512, 183-190.
68. Lohner, K., Prenner, E.J. Differential scanning calorimetry and x-ray diffraction studies of the specificity of the interaction of antimicrobial peptides with membrane-mimetic systems. Biophys. Biochim. Acta 1999, 1462, 141-156.
69. Bystrom, T., Strandberg, E., Kovacs, F.A., Cross, T.A., Lindblom, G. Influence of transmembrane peptides on bilayers of phosphatidylcholines with different acyl chain lengths studied by solid-state NMR.. Biophys. Biochim. Acta 2000, 1509, 335-345.
70. Auger, M. Membrane structure and dynamics as viewed by solid-state NMR spectroscopy. Biophysical Chemistry 1977, 68, 233-241.
71. 13C-NMR studies. Biochim. Biophys. Acta 1990, 1026, 225-235.
72. 31P-nuclear magnetic spectroscopy with Differential Scanning Calorimetry to study cannabinoid-membrane interactions. Chem. Phys. Lipids 1998, 92, 37-52.
73. Mavromoustakos, T.; Theodoropoulou, E.; De-Ping Yang. The use of high-resolution solid-state NMR spectroscopy and differential scanning calorimetryto study interactions of anaesthetic steroids with membrane. Biochim. Biophys. Acta 1997, 1328, 65-73.
74. Mavromoustakos, T.; Yang, D.P.; Broderick, W.; Fournier, D.; Herbette, L.G.; Makriyannis, A. Small Angle X-Ray Diffraction Studies on the Topography of cannabinoids in Synaptic Plasma Membranes. Pharmacol. Biochem. Be. 1991, 40, 547-552.
75. 2H-NMR. Biochim. Biophys. Acta 1992, 1103, 25-36.
76. 16-analog on the thermotropic properties of membrane bilayers. A model for membrane perturbation. Biochim. Biophys. Acta 1995, 1239(2), 257-264.
77. Mavromoustakos, T.; Theodoropoulou, E.; De-Ping Yang. The use of high-resolution solid-state NMR spectroscopy and differential scanning calorimetry to study interactions of anaesthetic steroids with membrane. Biochim. Biophys. Acta 1997, 1328, 65-73.
78. Cagigal, E.; Gonzalez, L.; Alonso, R.M.; Jimenez, R.M. pKa determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry. J. Pharm. Biomed. Anal. 2001, 26, 477-486.
79. Gillis, J.C.; Markham, A. Irbesartan: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997, 54, 885-452.
80. Rappolt M., Rapp, G. Structure of the metastable ripple phase of phosphatidylcholine. Eur. Biophys. 1996, J. 24, 381-386.
81. Press, K., Jorgensen, K., Laggner, P. Characterization of the submain-transition in disteaaroylphosphatidylcholine studied by simultaneous small- and wide-angle X-ray diffraction. Biochim. Biophys. Acta 1997, 1325, 1-7.
82. Lipowsky, R., Genetic interactions of flexible membranes in: Lipwsky, R.; Sackmann, E. (Eds.), Structure and Dynamics of Membranes. Generic and Specific Interactions, Handbook of Biological Physics, vol. 1B, Elsevier, Amsterdam, 1995, pp. 521-602.
83. Mavromoustakos, T.; Kolocouris, A.; Zervou, M.; Roumelioti, P.; Matsoukas, J.; Weisemann, R. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of NMR spectroscopy and theoretical calculations. J. Med. Chem. 1999, 42(10), 1714-1722.
84. 1Receptor Activation Is Dependent upon Two Juxtaposed Asparagine Residues on Transmembrane Helices III and VII. J. Biol. Chem. 1997, 272, 4245-4251.
85. Tieleman, D.P.; Marrink, S.J.; Berendesen, H.J.C. A computer perspective of the membranes: molecular dynamics studies of lipid bilayer systems. Biochem. Biophys. Acta 1997, 1331, 235-270
86. Preston, R.; Rhodes, D.J.; Herbette, L.G. Reevaluating equi-librium and kinetic parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J. Med. Chem. 1991, 34, 869-877.